Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INCIRWD · Entity 5213 | PFO & PAO | July 07, 2026 | July 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IRONWOOD PHARMACEUTICALS INC
Report date July 07, 2026 · Filed July 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 313,680 |
Reported balance
After 2026-07-07 transaction · row 1
1 source rowRow 1 · 2026-07-07 · Sale · Disposed 127,890 · Balance 313,680 F1: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.50 to $4.57, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.50 to $4.57, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 07, 2026 Filed Jul 9, 2026 20:32 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 127,890 | $4.52 | $578,062.80 |
DisclosureSEC source: 0001193125-26-299749 · ownership.xml · nonDerivative · entry 1 Silver Ronald · CIK 0001873731 · PFO & PAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 313,680 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.50 to $4.57, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 19, 2026 Filed May 21, 2026 20:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-234397 · ownership.xml · nonDerivative · entry 1 Silver Ronald · CIK 0001873731 · PFO & PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 441,570 F1 · kind: The restricted stock unit award vests as to 50% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 163,934 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-104110 · ownership.xml · nonDerivative · entry 1 Silver Ronald · CIK 0001873731 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 416,570 F1 · kind: The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 21:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 12,621 | $3.66 | $46,192.86 |
DisclosureSEC source: 0001193125-26-071495 · ownership.xml · nonDerivative · entry 2 Silver Ronald · CIK 0001873731 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,636 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the reporting person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.60 to $3.73, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 21:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 11,552 | $3.81 | $44,013.12 |
DisclosureSEC source: 0001193125-26-071495 · ownership.xml · nonDerivative · entry 1 Silver Ronald · CIK 0001873731 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,257 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.70 to $4.05, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 35,416 | $4.60 | $162,913.60 |
DisclosureSEC source: 0001193125-26-006290 · ownership.xml · nonDerivative · entry 1 Silver Ronald · CIK 0001873731 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 276,809 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: The reporting person acquired 35,416 shares of Class A Common Stock under the issuer's employee stock purchase plan on December 31, 2025. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 20:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,846 | $0.84 | $2,390.64 |
DisclosureSEC source: 0000950170-25-108011 · ownership.xml · nonDerivative · entry 1 Silver Ronald · CIK 0001873731 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 276,809 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 10, 2025 Filed Feb 13, 2025 02:00 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 12,048 | $1.76 | $21,204.48 |
DisclosureSEC source: 0000950170-25-019236 · ownership.xml · nonDerivative · entry 1 Silver Ronald · CIK 0001873731 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 279,655 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.60 to $1.84, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 22:30 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 133,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-010598 · ownership.xml · nonDerivative · entry 1 Silver Ronald · CIK 0001873731 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 291,703 F1 · kind: The restricted stock unit award, granted as a promotion award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 21:08 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 3,107 | $4.27 | $13,266.89 |
DisclosureSEC source: 0000950170-24-097182 · ownership.xml · nonDerivative · entry 1 Silver Ronald · CIK 0001873731 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,370 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 12, 2024 Filed Feb 15, 2024 01:50 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 27,213 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-015553 · ownership.xml · nonDerivative · entry 2 Silver Ronald · CIK 0001873731 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,477 F3 · kind: The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
| February 12, 2024 Filed Feb 15, 2024 01:50 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 7,908 | $15.24 | $120,517.92 |
DisclosureSEC source: 0000950170-24-015553 · ownership.xml · nonDerivative · entry 1 Silver Ronald · CIK 0001873731 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,264 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.85 to $15.53, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 29, 2023 Filed Aug 31, 2023 20:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-047842 · doc4.xml · nonDerivative · entry 1 Silver Ronald · CIK 0001873731 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,172 F1 · kind: The restricted stock unit award, granted as a recognition award, vests as to 50% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 20:21 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,976 | $10.04 | $19,839.04 |
DisclosureSEC source: 0001209191-23-046018 · doc4.xml · nonDerivative · entry 1 Silver Ronald · CIK 0001873731 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,172 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · balance_after: The reporting person acquired 2,037 shares of Class A Common Stock under the issuer's employee stock purchase plan on June 30, 2023. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 22:15 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 35,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-017892 · doc4.xml · nonDerivative · entry 1 Silver Ronald · CIK 0001873731 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,111 F1 · kind: The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
| February 28, 2023 Filed Mar 1, 2023 23:25 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 3,049 | $11.31 | $34,484.19 |
DisclosureSEC source: 0001209191-23-014286 · doc4.xml · nonDerivative · entry 2 Silver Ronald · CIK 0001873731 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,491 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.26 to $11.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 23:25 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,929 | $11.41 | $33,419.89 |
DisclosureSEC source: 0001209191-23-014286 · doc4.xml · nonDerivative · entry 1 Silver Ronald · CIK 0001873731 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,540 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.29 to $11.53, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 21, 2022 Filed Nov 23, 2022 21:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 682 | $11.56 | $7,883.92 |
DisclosureSEC source: 0001209191-22-058612 · doc4.xml · nonDerivative · entry 1 Silver Ronald · CIK 0001873731 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,469 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,014 | $11.77 | $23,704.78 |
DisclosureSEC source: 0001209191-22-046225 · doc4.xml · nonDerivative · entry 1 Silver Ronald · CIK 0001873731 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,151 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · balance_after: The reporting person acquired 2,092 shares of Class A Common Stock under the issuer's employee stock purchase plan on June 30, 2022. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 120 | $11.50 | $1,380.00 |
DisclosureSEC source: 0001209191-22-031843 · doc4.xml · nonDerivative · entry 1 Silver Ronald · CIK 0001873731 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,073 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on April 1, 2019. Read SEC document |
| March 24, 2022 Filed Mar 25, 2022 20:07 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 3,031 | $12.75 | $38,645.25 |
DisclosureSEC source: 0001209191-22-021097 · doc4.xml · nonDerivative · entry 1 Silver Ronald · CIK 0001873731 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,193 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016188 · doc4.xml · nonDerivative · entry 2 Silver Ronald · CIK 0001873731 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,224 F2 · kind: The restricted stock unit award, granted as a promotion award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 17,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016188 · doc4.xml · nonDerivative · entry 1 Silver Ronald · CIK 0001873731 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,224 F1 · kind: The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:01 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,150 | $10.77 | $12,385.50 |
DisclosureSEC source: 0001209191-22-014661 · doc4.xml · nonDerivative · entry 3 Silver Ronald · CIK 0001873731 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,211 F4 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 23, 2021. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:01 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 640 | $10.77 | $6,892.80 |
DisclosureSEC source: 0001209191-22-014661 · doc4.xml · nonDerivative · entry 2 Silver Ronald · CIK 0001873731 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,361 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2020. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:01 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 448 | $10.77 | $4,824.96 |
DisclosureSEC source: 0001209191-22-014661 · doc4.xml · nonDerivative · entry 1 Silver Ronald · CIK 0001873731 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,001 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 29, 2019. F2 · balance_after: The reporting person acquired 2,236 shares of Class A Common Stock under the issuer's employee stock purchase plan on June 30, 2021. Read SEC document |
| November 23, 2021 Filed Nov 24, 2021 21:07 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 713 | $11.58 | $8,256.54 |
DisclosureSEC source: 0001209191-21-066779 · doc4.xml · nonDerivative · entry 2 Silver Ronald · CIK 0001873731 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,213 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 50% of the reporting person's restricted stock units granted on December 4, 2020. Read SEC document |
| November 23, 2021 Filed Nov 24, 2021 21:07 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 749 | $11.58 | $8,673.42 |
DisclosureSEC source: 0001209191-21-066779 · doc4.xml · nonDerivative · entry 1 Silver Ronald · CIK 0001873731 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,926 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 100% of the reporting person's restricted stock units granted on December 16, 2019. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 20:06 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 567 | $13.48 | $7,643.16 |
DisclosureSEC source: 0001209191-21-052207 · doc4.xml · nonDerivative · entry 1 Silver Ronald · CIK 0001873731 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,675 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on September 1, 2020. Read SEC document |
| July 20, 2021 Filed Jul 22, 2021 20:14 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-047736 · doc4.xml · nonDerivative · entry 1 Silver Ronald · CIK 0001873731 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,242 F1 · kind: The restricted stock units, granted as a recognition award, vest as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.